medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2024, Número 4

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2024; 22 (4)


Usos off-label de la neurotoxina botulínica en dermatología. Una revisión narrativa

Ortegón BÁE, Achell NL

Idioma: Español
Referencias bibliográficas: 94
Paginas: 340-352
Archivo PDF: 293.78 Kb.


RESUMEN

La neurotoxina botulínica (NTB) es un agente terapéutico que, en principio, se desarrolló y empleó para corregir afecciones neurológicas, años después se descubrió y autorizó su uso con fines estéticos, ahora es el mayor uso que se le da a lo largo del mundo. Debido al bloqueo neuromuscular temporal altamente selectivo en la zona de aplicación, algunos médicos han descrito su posible utilidad terapéutica para el manejo de patologías dermatológicas de difícil control como prurito, piel grasa, acné, genodermatosis, alopecia, rosácea y eccema dishidrótico, por mencionar sólo algunos. Como la evidencia de estos usos se limita a reportes de casos o pequeños ensayos clínicos no aleatorizados, no se han podido incluir en las indicaciones aprobadas por las agencias reguladoras de fármacos en el mundo, por lo que permanece con la denominación off-label. El objetivo de este trabajo es presentar una revisión narrativa de los principales usos off-label de la NTB para entidades dermatológicas no cosméticas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Harvey SM, Sturgeon J y Dassey DE, Botulism due to Clostridiumbaratii type f toxin, J Clin Microbiol 2002; 40(6):2260.

  2. Monheit GD y Pickett A, Abobotulinumtoxina: a 25-year history,Aesthetic Surg J 2017; 37(1):S4-11.

  3. American Society of Plastic Surgery, Plastic Surgery Statics Report,2020.

  4. Wollina U, Konrad H y Petersen S, Botulinum toxin in dermatology:beyond wrinkles and sweat, J Cosmet Dermatol 2005;4(4):223-7.

  5. Kim Y, Hong E y Kim H, Botulinum toxin in the field of dermatology:novel indications, Toxins (Basilea) 2017; 9(12):403.

  6. Pantano S y Montecucco C, The blockade of the neurotransmitterrelease apparatus by botulinum neurotoxins, Cell Mol LifeSci 2014; 71(5):793-811.

  7. Rawson AM, Dempster AW, Humphreys CM y Minton NP, Pathogenicityand virulence of Clostridium botulinum, Virulence2023; 14(1).

  8. Masuyer G, Conrad J y Stenmark P, The structure of the tetanustoxin reveals pH mediated domain dynamics, embo Rep 2017;18(8):1306-17.

  9. Rossetto O, Pirazzini M y Montecucco C, Botulinum neurotoxins:genetic, structural and mechanistic insights, Nat Rev Microbiol2014; 12(8):535-49.

  10. Peck M, Smith T, Anniballi F et al., Historical perspectives andguidelines for botulinum neurotoxin subtype nomenclature, Toxins(Basilea) 2017; 9(1):38.

  11. Torii Y, Kiyota N, Sugimoto N et al., Comparison of effects ofbotulinum toxin subtype A1 and A2 using twitch tension assayand rat grip strength test, Toxicon 2011; 57(1):93-9.

  12. Elliott M, Maignel J, Liu SM et al., Augmentation of vamp-catalyticactivity of botulinum neurotoxin serotype b does not resultin increased potency in physiological systems, plos One2017; 12(10):e0185628.

  13. Fernández-García G, Toxina botulínica y sus aplicaciones clínicas,Npunto 2022; 49:88-110.

  14. Wadhwa M, Knezevic I, Kang HN y Thorpe R, Immunogenicityassessment of biotherapeutic products: an overview of assaysand their utility, Biologicals 2015; 43(5):298-306.

  15. Cárdenas-Colín L y Castillo-Chávez LM, Tolerancia inmune al tratamientocon toxina botulínica tipo a, Rev Cuba Reumatol 2016;XVIII(2):142-9.

  16. Roberto-Antonio C, Antonio JR, Arroyo Trídico L y Aidar FernandesÉT, Toxina botulínica: revisão de sua aplicabilidade emdoenças ao alcance do dermatologista, Surg Cosmet Dermatology2014; 6(3):668-76.

  17. Spiegel LL, Ostrem JL y Bledsoe IO, fda approvals and consensusguidelines for botulinum toxins in the treatment of dystonia,Toxins (Basilea) 2020; 12(5):332.

  18. Frampton JE y Silberstein S, Onabotulinumtoxina: a review inthe prevention of chronic migraine, Drugs 2018; 78(5):589-600.

  19. Choudhury S, Baker MR, Chatterjee S y Kumar H, Botulinumtoxin: an update on pharmacology and newer products in development,Toxins (Basilea) 2021; 13(1):58.

  20. Hallett M, Albanese A, Dressler D et al., Evidence-based reviewand assessment of botulinum neurotoxin for the treatment ofmovement disorders, Toxicon 2013; 67:94-114.

  21. Food and Drugs Administration, 103000, Drugs@fda: fda approveddrugs, 2022. Consultado el 7 de julio de 2023. Disponible en:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103000.

  22. Food and Drugs Administration, Xeomin-Label, 2021. Consultadoel 7 de julio de 2023. Disponible en: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125360lbl.pdf.

  23. Sugarman JH, Fleischer AB y Feldman SR, Off-label prescribingin the treatment of dermatologic disease, J Am Acad Dermatol2002; 47(2):217-23.

  24. França K y Litewka S, Controversies in off‐label prescriptions indermatology: the perspective of the patient, the physician, and thepharmaceutical companies, Int J Dermatol 2019; 58(7):788-94.

  25. Berman B, Maderal A y Raphael B, Keloids and hypertrophicscars: pathophysiology, classification, and treatment, DermatologicSurg 2017; 43(1):S3-18.

  26. Xiao Z, Zhang M, Liu Y y Ren L, Botulinum toxin type a inhibitsconnective tissue growth factor expression in fibroblastsderived from hypertrophic scar, Aesthetic Plast Surg 2011;35(5):802-7.

  27. Jeong HS, Lee BH, Sung HM et al., Effect of botulinum toxintype a on differentiation of fibroblasts derived from scar tissue,Plast Reconstr Surg 2015; 136(2):171e-8.

  28. Higuerey Morao DJ, Soto Montenegro AE y Giorginaani ColmenaresGS, Toxina botulínica tipo a en el tratamiento del queloide,Cir Plást Iberolatinoam 2021; 47(2):187-200.

  29. Shaarawy E, Hegazy RA y Abdel Hay RM, Intralesional botulinumtoxin type a equally effective and better tolerated thanintralesional steroid in the treatment of keloids: a randomizedcontrolled trial, J Cosmet Dermatol 2015; 14(2):161-6.

  30. Lee BJ, Jeong JH, Wang SG, Lee JC, Goh EK y Kim HW, Effectof botulinum toxin type a on a rat surgical wound model, ClinExp Otorhinolaryngol 2009; 2(1):20.

  31. Xiao Z, Zhang F y Cui Z, Treatment of hypertrophic scars withintralesional botulinum toxin type a injections: a preliminary report,Aesthetic Plast Surg 2009; 33(3):409-12.

  32. Lee SH, Min HJ, Kim YW y Cheon YW, The efficacy and safety ofearly postoperative botulinum toxin a injection for facial scars,Aesthetic Plast Surg 2018; 42(2):530-7.

  33. Yang W y Li G, The safety and efficacy of botulinum toxin type ainjection for postoperative scar prevention: a systematic reviewand meta‐analysis, J Cosmet Dermatol 2020; 19(4):799-808.

  34. Qiao Z, Yang H, Jin L, Li S y Wang X, The efficacy and safety ofbotulinum toxin injections in preventing postoperative scars andimproving scar quality: a systematic review and meta-analysis,Aesthetic Plast Surg 2021; 45(5):2350-62.

  35. Fu Z, Huang H y Huang J, Efficacy and safety of botulinum toxintype a for postoperative scar prevention and wound healing improvement:a systematic review and meta‐analysis, J CosmetDermatol 2022; 21(1):176-90.

  36. Yue S, Ju M y Su Z, A systematic review and meta-analysis:botulinum toxin a effect on postoperative facial scar prevention,Aesthetic Plast Surg 2022; 46(1):395-405.

  37. Sutaria N, Adawi W, Goldberg R, Roh YS, Choi J y Kwatra SG,Itch: pathogenesis and treatment, J Am Acad Dermatol 2022;86(1):17-34.

  38. Huang SH, Wu KW, Lo JJ y Wu SH, Synergic effect of botulinumtoxin type a and triamcinolone alleviates scar pruritus by modulatingepidermal hyperinnervation: a preliminary report, AestheticSurg J 2021; 41(11):np1721-31.

  39. Toyama S, Tominaga M y Takamori K, Treatment options for troublesomeitch, Pharmaceuticals 2022; 15(8):1022.

  40. Ramachandran R, Marino M, Paul S et al., A study and reviewof effects of botulinum toxins on mast cell dependent and independentpruritus, Toxins (Basilea) 2018; 10(4):134.

  41. Gazerani P, Pedersen NS, Drewes AM y Arendt-Nielsen L, Botulinumtoxin type a reduces histamine-induced itch and vasomotorresponses in human skin, Br J Dermatol 2009; 161(4):737-45.

  42. Weidinger S, Beck LA, Bieber T, Kabashima K e Irvine AD, Atopicdermatitis, Nat Rev Dis Prim 2018; 4(1):1.

  43. Endly DC y Miller RA, Oily skin: a review of treatment options,J Clin Aesthet Dermatol 2017; 10(8):49-55.

  44. Li ZJ, Park SB, Sohn KC et al., Regulation of lipid production byacetylcholine signalling in human sebaceous glands, J DermatolSci 2013; 72(2):116-22.

  45. Angelo-Khattar M, The non-cosmetic dermatological use of botulinumneurotoxin. En Sabuncuoglu S (ed.), Botulinum toxin:recent topics and applications, IntechOpen, 2022.

  46. Min P, Xi W, Grassetti L et al., Sebum production alteration afterbotulinum toxin type a injections for the treatment of foreheadrhytides: a prospective randomized double-blind dose-comparativeclinical investigation, Aesthetic Surg J 2015; 35(5):600-10.

  47. Santesteban Muruzábal R, Hervella Garcés M y Ros MartínC, ¿Qué genodermatosis es?, Actas Dermosifiliogr 2015;106(8):667-8.

  48. Salik D, Richert B y Smits G., Clinical and molecular diagnosis ofgenodermatoses: review and perspectives, J Eur Acad DermatologyVenereol 2023; 37(3):488-500.

  49. Gharib K, Mostafa A y Elsayed A, Evaluation of botulinum toxintype a injection in the treatment of localized chronic pruritus”, JClin Aesthet Dermatol 2020; 13(12):12-7.

  50. Khattab FM, Evaluation of botulinum toxin a as an optionaltreatment for atopic dermatitis, J Clin Aesthet Dermatol 2020;13(7):32-5.

  51. Shah AR, Use of intradermal botulinum toxin to reduce sebumproduction and facial pore size, J Drugs Dermatol 2008;7(9):847-50.

  52. Rose AE y Goldberg DJ, Safety and efficacy of intradermal injectionof botulinum toxin for the treatment of oily skin, DermatologicSurg 2013; 39(3):443-8.

  53. Bar‐Ilan E, Koren A, Shehadeh W, Mashiah J, Sprecher E y ArtziO, An enhanced transcutaneous delivery of botulinum toxinfor the treatment of Hailey-Hailey disease, Dermatol Ther 2020;33(1):e13184.

  54. Zhang H, Tang K, Wang Y, Fang R y Sun Q, Botulinum toxin intreating Hailey‐Hailey disease: a systematic review, J CosmetDermatol 2021; 20(5):1396-402.

  55. Dreyfus I, Maza A, Rodríguez L et al., Botulinum toxin injectionsas an effective treatment for patients with intertriginous Hailey-Hailey or Darier disease: an open-label 6-month pilot interventionalstudy, Orphanet J Rare Dis 2021; 16(1):93.

  56. Kontochristopoulos G, Katsavou A, Kalogirou O, Agelidis S yZakopoulou N, Letter: botulinum toxin type a: an alternativesymptomatic management of Darier’s disease, DermatologicSurg 2007; 33(7):882-3.

  57. Santiago-et-Sánchez-Mateos JL, Beà S, Fernández M, Pérez B,Harto A y Jaén P, Botulinum toxin type a for the preventive treatmentof intertrigo in a patient with Darier’s disease and inguinalhyperhidrosis, Dermatologic Surg 2008; 34(12):1733-7.

  58. Holahan HM, Farah RS, Ferguson NN, Paller AS y Legler AA,Treatment of symptomatic epidermolysis bullosa simplex withbotulinum toxin in a pediatric patient, jaad Case Reports 2016;2(3):259-60.

  59. Swartling C y Vahlquist A, Treatment of pachyonychia congenitawith plantar injections of botulinum toxin, Br J Dermatol 2006;154(4):763-5.

  60. González-Ramos J, Sendagorta-Cudós E, González-López G,Mayor-Ibarguren A, Feltes-Ochoa R y Herranz-Pinto P, Efficacyof botulinum toxin in pachyonychia congenita type 1: report oftwo new cases, Dermatol Ther 2016; 29(1):32-6.

  61. Koren A, Sprecher E, Reider E y Artzi O, A treatment protocolfor botulinum toxin injections in the treatment of pachyonychiacongenita‐associated keratoderma, Br J Dermatol 2020;182(3):671-7.

  62. Tamura BM, Sortino-Rachou AM y Cucé LC, Letter: folliculitisresponds to botulinum toxin: is it possible?, Dermatologic Surg2007; 33(11):1398-400.

  63. Freund BJ y Schwartz M, Treatment of male pattern baldnesswith botulinum toxin: a pilot study, Plast Reconstr Surg 2010;126(5):246e-8.

  64. Zhang L, Yu Q, Wang Y, Ma Y, Shi Y, Li X, A small dose of botulinumtoxin a is effective for treating androgenetic alopecia inChinese patients, Dermatol Ther 2019; 32(4):e12785.

  65. Wang Y, Zhang H, Zheng Q, Tang K, Fang R y Sun Q, Botulinumtoxin as a double‐edged sword in alopecia: a systematic review,J Cosmet Dermatol 2020; 19(10):2560-5.

  66. Wijaya H y Winaya KK, Androgenetic alopecia in woman treatedwith botulinum toxin, Intisari Sains Medis 2021; 12(3):1050-3.

  67. Yu V, Juhász M, Chiang A y Atanaskova Mesinkovska N, Alopeciaand associated toxic agents: a systematic review, SkiAppendage Disord 2018; 4(4):245-60.

  68. Zhang M y Zhang N, Quality of life assessment in patients withalopecia areata and androgenetic alopecia in the People’s Republicof China, Patient Prefer Adherence 2017; 11:151-5.

  69. Kowing D, Madarosis and facial alopecia presumed secondary tobotulinum a toxin injections, Optom Vis Sci 2005; 82(7):579-82.

  70. Cutrer F, Sandroni P y Wendelschafer-Crabb G, Botulinum toxintreatment of cephalalgia alopecia increases substance p andcalcitonin gene-related peptide-containing cutaneous nerves inscalp, Cephalalgia 2010; 30(8):1000-6.

  71. Cutrer F y Pittelkow M, Cephalalgic alopecia areata, Cephalalgia2006; 26(6):747-51.

  72. Jung BH, Song SH, Yoon SJ, Koo JH y Yoo KY, The effect of botulinumtoxin on hair follicle cell regeneration under continuousstress conditions: a pilot animal study, Neurotox Res 2022;40(1):103-10.

  73. Zuuren EJ, Fedorowicz Z, Tan J et al., Interventions for rosaceabased on the phenotype approach: an updated systematicreview including grade assessments, Br J Dermatol 2019;181(1):65-79.

  74. Kang CNY, Shah M y Tan J, Rosacea: an update in diagnosis, classificationand management, Skin Therapy Lett 2021; 26(4):1-8.

  75. Mascarenhas NL, Wang Z, Chang YL y Di Nardo A, trpv4 mediatesmast cell activation in cathelicidin-induced rosacea inflammation,J Invest Dermatol 2017; 137(4):972-5.

  76. Choi JE, Werbel T, Wang Z, Wu CC, Yaksh TL y Di Nardo A, Botulinumtoxin blocks mast cells and prevents rosacea like inflammation,J Dermatol Sci, 2019; 93(1):58-64.

  77. Yuraitis M y Jacob CI, Botulinum toxin for the treatment of facialflushing, Dermatologic Surg 2004; 30(1):102-4.

  78. Kranendonk SK, Ferris LK y Obagi S. Re: botulinum toxin for thetreatment of facial flushing, Dermatologic Surg 2005; 31(4): 491.

  79. Wollina U, Pompholyx, Am J Clin Dermatol 2010; 11(5):305-14.

  80. Swartling C, Naver H, Lindberg M y Anveden I, Treatment ofdyshidrotic hand dermatitis with intradermal botulinum toxin, JAm Acad Dermatol 2002; 47(5):667-71.

  81. Wollina U y Karamfilov T, Adjuvant botulinum toxin a in dyshidrotichand eczema: a controlled prospective pilot study withleft-right comparison, J Eur Acad Dermatology Venereol 2002;16(1):40-2.

  82. Bloom BS, Payongayong L, Mourin A y Goldberg DJ, Impact ofintradermal abobotulinumtoxina on facial erythema of rosacea,Dermatologic Surg 2015; 41(Supp 1):S9-16.

  83. Eshghi G, Khezrian L y Alirezaei P, Botulinum toxin a in treatmentof facial flushing, Acta Med Iran 2016; 54(7):454-7.

  84. Kim MJ, Kim JH, Cheon HI et al., Assessment of skin physiologychange and safety after intradermal injections with botulinumtoxin: a randomized, double-blind, placebo-controlled,split-face pilot study in rosacea patients with facial erythema,Dermatologic Surg 2019; 45(9):1155-62.

  85. Al‐Niaimi F, Glagoleva E y Araviiskaia E, Pulsed dye laser followedby intradermal botulinum toxin type‐a in the treatmentof rosacea‐associated erythema and flushing, Dermatol Ther2020; 33(6).

  86. Vasconcellos JB, Santos IO y Antelo DAP, Use of botulinum toxinfor rosacea: a pilot study, Surg Cosmet Dermatology 2021;13:e20210019.

  87. Ismail A, El‐Kholy S y Farid C, Botulinum toxin type a in chronicnon‐dyshidrotic palmar eczema: a side‐by‐side comparativestudy, J Dermatol 2020; 47(6):601-8.

  88. Zagui RMB, Matayoshi S y Moura FC, Efeitos adversos associadosà aplicação de toxina botulínica na face: revisão sistemáticacom meta-análise, Arq Bras Oftalmol 2008; 71(6):894-901.

  89. Zargaran D, Zoller F, Zargaran A et al., Complications of cosmeticbotulinum toxin a injections to the upper face: a systematicreview and meta-analysis, Aesthetic Surg J 2022; 42(5):np327-36.

  90. Yeh YT, Peng JH y Peng HLP, Literature review of the adverseevents associated with botulinum toxin injection for the massetermuscle hypertrophy, J Cosmet Dermatol 2018; 17(5):675-87.

  91. Kwon JS, Kim ST, Jeon YM y Choi JH, Effect of botulinum toxintype a injection into human masseter muscle on stimulated parotidsaliva flow rate, Int J Oral Maxillofac Surg 2009; 38(4):316-20.

  92. Landau M, Nestor MS, Almeida AT y Al‐Niaimi F, Botulinumtoxin complications in registered and off‐label aesthetic indications,J Cosmet Dermatol 2020; 19(10):2484-90.

  93. Yiannakopoulou E, Serious and long-term adverse events associatedwith the therapeutic and cosmetic use of botulinumtoxin, Pharmacology 2015; 95(1-2):65-9.

  94. Scaglione F, Conversion ratio between Botox®, Dysport®, andXeomin® in clinical practice, Toxins (Basilea) 2016; 8(3):65.




2020     |     www.medigraphic.com